Business Model Breakdown
How Amicus Therapeutics Inc Makes Money
FOLD
Market Cap
$4.5B
Profit Margin
-4.3%
Employees
499
The Short Version
Prior to its acquisition by BioMarin, Amicus Therapeutics (FOLD) was a global biotechnology company focused on developing and commercializing innovative medicines for people living with rare metabolic diseases. It generated revenue primarily through the sale of its approved therapies, Galafold for Fabry disease and the Pombiliti + Opfolda (AT-GAA) combination for Pompe disease, targeting significant unmet needs in these specialized markets. Its business model relied on drug discovery, clinical development, regulatory approvals, and global commercialization, leveraging its scientific expertise in enzyme replacement and chaperone therapies.
Where the Revenue Comes From
Galafold sales for Fabry disease (primary revenue pre-merger)
Pombiliti + Opfolda sales for Pompe disease (recently launched, growing contribution pre-merger)
Who buys: Patients diagnosed with Fabry disease or Pompe disease, along with healthcare providers and specialized clinics.
Why It Works (Competitive Advantages)
- ✔Not applicable for FOLD as an independent entity; its previous advantages are now part of BioMarin's portfolio.
Economic Moat: None (as a standalone, delisted entity) (Not applicable for FOLD as an independent entity; its previous moats (Intangible Assets/IP from rare disease therapies) are now part of BioMarin.)
What Our Analysis Says
DVR Score as of May 1, 2026
Amicus Therapeutics (FOLD) was acquired by BioMarin Pharmaceutical for $14.50 cash per share on April 27, 2026, leading to its delisting from Nasdaq on April 28, 2026. This fundamental change means FOLD no longer exists as an independent publicly traded entity. Consequently, it offers no future investment potential, let alone a '10x growth potential,' for new or existing investors, as shares are no longer traded and have been converted to cash at a fixed price. The previous analysis, which identified significant upside tempered by execution risk, is now entirely superseded by the acquisition event. The company's vision, competitive advantages, financial health, leadership, catalysts, and market sentiment are now integrated into BioMarin, making FOLD a non-investable entity for independent growth. **Score Change Explanation:** The previous analysis on 2025-10-05 (score 7.9/10 or 79/100) evaluated Amicus Therapeutics (FOLD) as an independent, publicly traded company with substantial 10x growth potential in rare disease markets, driven by products like Galafold and the promising AT-GAA, albeit with execution and financial sustainability risks. Since that analysis, the most material and definitive event has occurred: Amicus Therapeutics Inc. was acquired by BioMarin Pharmaceutical on April 27, 2026, at a fixed price of $14.50 per share, and its common stock has been delisted. This acquisition fundamentally alters FOLD's investment profile from a standalone growth opportunity to a non-existent public entity. The very premise of evaluating '10x growth potential' for FOLD as an independent stock is now entirely invalid. Therefore, the score has been adjusted from 79/100 to 0/100 to reflect that FOLD is no longer an investable security for future capital appreciation.